Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy.
Lamanna N, Tam CS, Woyach JA, Alencar AJ, Palomba ML, Zinzani PL, Flinn IW, Fakhri B, Cohen JB, Kontos A, Konig H, Ruppert AS, Chatterjee A, Sizelove R, Compte L, Tsai DE, Jurczak W.
Lamanna N, et al. Among authors: konig h.
EJHaem. 2024 Sep 27;5(5):929-939. doi: 10.1002/jha2.1013. eCollection 2024 Oct.
EJHaem. 2024.
PMID: 39415923
Free PMC article.